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Abstract  45 
 46 
Background: Falls are a major cause of morbidity among older people. Multifaceted interventions may be 47 
effective in preventing falls and related fractures. 48 
 49 
Objective: To evaluate the cost-effectiveness alongside the REFORM (REducing Falls with Orthoses and a 50 
Multifaceted podiatry intervention) trial. 51 
 52 
Methods: REFORM was a pragmatic multicentre cohort randomised controlled trial in England and Ireland; 1010 53 
participants (>65 years) were randomised to receive either a podiatry intervention (n= 493), including foot and 54 
ankle strengthening exercises, foot orthoses, new footwear if required, and a falls prevention leaflet, or usual 55 
podiatry treatment plus a falls prevention leaflet (n=517). Primary outcome: incidence of falls per participant in 56 
the 12 months following randomisation. Secondary outcomes : proportion of fallers and quality of life (EQ-5D-57 
3L) which was converted into quality-adjusted life years (QALYs) for each participant. Differences in mean costs 58 
and QALYs at 12 months were used to assess the cost-effectiveness of the intervention relative to usual care. 59 
Cost-effectiveness analyses were conducted in accordance with National Institute for Health and Clinical 60 
Excellence reference case standards, using a regression based approach with costs expressed in GBP (2015 price). 61 
The base case analysis used an intention to treat approach on the imputed data se t using multiple imputation (MI).  62 
 63 
Results: There was a small, non-statistically significant reduction in the incidence rate of falls in the intervention 64 
group (adjusted incidence rate ratio 0.88, 95% CI 0.73 to 1.05, p = 0.16). Participants allocated to the intervention 65 
group accumulated on average marginally higher QALYs than usual care participants (mean difference 0.0129, 66 
95% CI -0.0050 to 0.0314). The intervention costs on average £252 more per participant compared to usual care 67 
(95% CI -£69 to £589). Incremental cost-effectiveness ratios ranged between £19,494 and £20,593 per QALY 68 
gained, below the conventional NHS cost-effectiveness thresholds of £20,000 to £30,000 per additional QALY. 69 
The probability that the podiatry intervention is cost-effective at a threshold of £30,000 per QALY gained is 0.65. 70 
The results were robust to sensitivity analyses .   71 
 72 
Conclusion: The benefits of the intervention justified the moderate cost. The intervention could be a cost -effective 73 
option for falls prevention when compared with usual care in the UK.  74 
 75 
 76 
 77 
 78 
 79 
 80 
Trial registration number: ISRCTN68240461 81 
 82 
 83 
INTRODUCTION  84 
 85 
Falls are common among older people with a high cost to health care systems and society [1-3]. The cost burden 86 
of falls to the UK National Health Service (NHS) is estimated of more than £2 billion per year [4]. Given that the 87 
number of people over the age of 65 is predicted to increase, we might expect the cost of falls to the NHS to rise 88 
further every year. It has been suggested that podiatry care play a role in falls prevention, as cohort studies have 89 
indicated a relationship between risk of falling and both foot and ankle problems [5, 6] and inappropriate footware 90 
[7]. There is evidence that a multifaceted podiatry intervention  ±which combines foot and ankle exercise, foot 91 
orthoses, foot advise and a falls prevention booklet combined with routine podiatry care - is effective at reducing 92 
the incidence of falls among older people in an Australian setting [8]. This trial did not include an economic 93 
evaluation.  94 
 95 
The REFORM (REducing Falls with Orthoses and a Multifaceted podiatry intervention) trial evaluated the clinical 96 
and cost-effectiveness of a multifaceted podiatric intervention aimed at  reducing the incidence of falls among 97 
people at high risk of falling within the UK setting [9]. There was a non-statistically significant reduction in the 98 
incidence rate of falls in the intervention group [adjusted incidence ratio 0.88; 95% confidence interval (CI) 0.73 99 
to 1.05; p=0.16]. However, the proportion of participants experiencing a fall was reduced (50 vs 55%, adjusted 100 
odds ratio 0.78; 95% CI 0.60 to 1.00; p=0.05). Hence, there is a potential to improve health related quality of life 101 
(HRQOL) by preventing falls and to reduce health care costs. From an economic perspective, the recommendation  102 
is that estimation, and not hypothesis testing, be used to inform decision making for resource allocation in health 103 
care [10]. Therefore it remains important to assess whether the benefits of the intervention justify the extra costs 104 
of providing the multifaceted programme; addressing this will be important in order to deliver improved services 105 
to this population that offer good value for money to the NHS. This paper reports on the economic evaluation 106 
conducted alongside the REFORM trial.  107 
 108 
METHODS 109 
 110 
Overview  111 
We conducted a pragmatic open two-arm, cohort randomised controlled trial [11] with an economic evaluation. 112 
The REFORM protocol has been published elsewhere [12]. In summary, participants  were recruited to an 113 
observational cohort study from podiatric clinic lists in the UK and the Republic of Ireland  and followed up for 114 
falls data. Participants, who fulfilled the REFORM trial eligibility criteria, were then randomised into the trial, 115 
when podiatrists had capacity to deliver the trial intervention .  All participants received routine podiatry care 116 
which typically aimed to reduce painful conditions such as corns , callouses and pathological nails, which have 117 
been found to be associated with an increased risk of falls.  In addition to this, all participants received a falls  118 
prevention leaflet produced by Age UK (Staying Steady June 2010) along with a group specific trial newsletter 119 
informing them about the progress of the trial.  Participants allocated to the intervention group additionally  120 
received footwear advice, provision of new footwear if current footwear was judged to be inappropriate (supplied 121 
by Hotter Footwear® and DB Shoes Ltd); foot orthoses (x-line®, Healthystep, Mossley, UK); and a 30 minutes 122 
a day, three times a week home-based foot and ankle exercise programme supplemented with a DVD and 123 
explanatory booklet [8]. Intervention participants were invited to attend two podiatry appointments, with further 124 
appointments offered if required.  125 
 126 
A cost-utility analysis with health outcomes expressed in terms of quality -adjusted life years (QALYs) in 127 
accordance with the NICE (National Institute for Health and Clinical Excellence) reference case [13] was 128 
undertaken. Cost-effectiveness in terms of cost per fall everted was assessed for comparison. The evaluation took 129 
the perspective of the NHS and personal social services for a time horizon of 12 months; with costs presented in 130 
UK pounds sterling at 2015 prices. A regression approach on an intention-to-treat basis was used. The base-case 131 
analysis was conducted on the dataset generated by multiple imputation (MI) methods [14]. Sensitivity analysis 132 
included complete-case (CC) analysis to test the impact of excluding participants with missing data on the final 133 
results. All analyses and modelling were conducted in Stata 13.1 (StataCorp 2011, TX, USA).  134 
 135 
Health outcomes 136 
The primary outcome measure was QALYs. Therefore, in addition to the participant -reported outcomes described 137 
in the clinical paper [9], participants also completed the EQ-5D-3L (EuroQoL Group Rotterdam, The Netherlands) 138 
at baseline, six and 12 months post-randomisation. The EQ-5D-3L is comprised of five dimensions of health status 139 
(mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with three severity levels (no, 140 
some, extreme problems/unable to) for each dimension. The EQ-5D has been recommended by The Prevention 141 
of Falls Network Europe Consensus as a measure of health  related quality of life (HRQoL) in trials [15] and has 142 
been used before in UK settings assessing HRQoL implications of falls in older people [2]. The EQ-5D-3L health 143 
states were converted into utilities using a UK-based social tariff [16]. A utility of one indicates perfect health, a 144 
XWLOLW\RI]HURLQGLFDWHV³DVEDGDVGHDWK´DQGQHJDWLYHXWLOLWLHVLGHQWLI\VWDWHVFRQVLGHUHGZRUVHWKDQGHDWK7KHVH145 
utilities were used to weight duration of survival and estimate QALYs, that were calculated using the area under 146 
the curve method [17] and were adjusted for baseline utility [18].  147 
 148 
Resource use and costs 149 
Resource use associated with falls was collected prospectively using participant-reported questionnaires  at 150 
baseline, six and 12 months. We collected information on resource use that we considered could potentially relate 151 
to the intervention, to allow us to assess the possibility that the provision of the multifaceted intervention prevents 152 
costs that would otherwise be incurred. Hence we asked participants to report visits to primary care professionals 153 
(General Practitioner (GP) and GP nurse), community care (occupational therapist), hospitalisations (inpatient, 154 
day-case, outpatient and A&E) and visits to podiatry clinics. The cost of the podiatry intervention was assessed 155 
based on the data collected as part of a baseline appointment questionnaire and the podiatrist database, which 156 
included information directly related to the podiatrist assessments and the intervention package received by the 157 
participant (e.g. orthosis prescription, exercise programme and exercise equipment). Participants allocated to the 158 
intervention would receive at least one baseline visit to the podiatrist plus at least one follow-up appointment. The 159 
first appointment was assumed to last for 1 hour; the second appointment for 30 minutes and all the rest were 160 
assumed to be the same duration as a GP clinic consultation (11.7 minutes). The cost for the visits was estimated 161 
according to NHS pay scales  on the Agenda for Change  for NHS podiatrist staff in England, Wales, Scotland and 162 
Northern Ireland (https://healthcareers.nhs.uk/ glossary#Agenda_for_Change). Podiatrists delivering the 163 
intervention ranged from band 6 to band 8. The base-case analysis includes only costs falling within the NHS and, 164 
hence, the cost of the provision of new footwear was not considered in the analysis . The total cost per each 165 
participant was estimated by multiplying each resource use item by their associated unit costs (Table 1). 166 
 167 
Handling missing data 168 
Complete case (CC) assessment excludes all participants with any missing or incomplete data. To avoid biases 169 
associated with CC analysis [19] incomplete data on cost and QALYs were handled using multiple imputation  170 
analysis assuming the data were missing at random (MAR), via chained equations and predictive mean matching  171 
[20, 21]. The same set of covariates as in the clinical effectiveness analysis was selected for the analysis (age, sex, 172 
history of falls, centre, costs and utilities). Rubin´s rules were used to combine point and variance estimates across 173 
imputed datasets, allowing the estimation of the difference in costs and QALYs between both groups. Five 174 
imputed data sets were generated as this has been deemed sufficient to obtain valid responses [22, 23]. Despite 175 
MI being the most robust method to handle missing data in economic evaluation, we analysed the pattern of 176 
missing data following economic guidelines [24] to ensure that the pattern of REFORM data reflects the 177 
assumption made for the base-case analysis (e.g. data are MAR). The association between missingness and 178 
baseline variables was explored by means of logistic regression.  179 
 180 
Base case analysis 181 
The base-case analysis was conducted on the imputed dataset on an intention to treat (ITT) basis, and included 182 
only fall-related health care visits. Since the NHS will not cover the cost of the provision of new footwear this 183 
was not considered for the base-case analysis.  184 
 185 
The cost-effectiveness of the intervention was calculated by comparing the mean differences in expected costs 186 
and QALYs between the two groups [25]. If the intervention (or usual care) is less costly and more effective, it 187 
ZRXOGµGRPLQDWH¶ the alternative and hence be considered cost-effective. If not, the incremental cost-effectiveness 188 
ratio (ICER) would be estimated as the difference in mean total costs at one year divided by the difference in 189 
mean total QALYs for the intervention compared to usual care. The mean estimates and their 95% confidence 190 
intervals (CI) were generated by means of seemingly unrelated regression (SUR) using bias corrected and 191 
accelerated (BCA) bootstrap methods. According to NICE, the cost-effectiveness threshold (e.g. quantity that the 192 
NHS is willing to pay (WTP) per person for an additional QALY ranges from £20,000 to £30,000 per QALY 193 
gained. The ICER was also arranged in terms of net monetary benefit (NMB), which translate the health benefits 194 
into monetary value using the cost-effectiveness thresholds (e.g. incremental QALYs multiplied by the WTP 195 
threshold) [26]. The intervention would be considered cost-effective if the NMB were positive. Non-parametric 196 
bootstrapping was used to determine the level of sample uncertainty associated with the mean ICER by generating 197 
5,000 estimates of incremental costs and benefits, represented graphically  198 
in a cost-effectiveness plane and a cost-effectiveness acceptability curve that shows the probability that the 199 
intervention is more cost-effective than usual care for a range of cost-effectiveness thresholds.  200 
 201 
Cost per fall averted 202 
Cost-effectiveness was also estimated in terms of falls prevented following guidelines for economic evaluation of 203 
fall prevention strategies [27]. This other form of analysis has the potential to strengthen the case for the 204 
multifaceted intervention by exploring the cost per fall averted and how this links to health care saving. The 205 
number of falls averted was estimated as the difference in mean reduction in the fall rate between the two groups 206 
in the trial estimated as per the adjusted negative binomial model.  207 
 208 
Sensitivity analysis 209 
Several sensitivity analysis were undertaken to assess the impact of uncertainty on the economic evaluation. These 210 
were conducted to test the robustness of the results using four scenarios: (i) restricting the analysis to CC, assuming 211 
the data were missing completely at random (MCAR); (ii) MI by imputing HRQoL at an aggregated level (e.g., 212 
at QALYs level); (iii) MI recalculating the average costs including both fall and non-fall resource use; and (iv) 213 
MI from a wider societal perspective that included costs incurred by the patients (e.g., cost of the shoes as a 214 
personal expense for the patient).  215 
 216 
HRQoL beyond the trial 217 
HRQoL was extrapolated to 5 years to explore how the differences in HRQoL evolve beyond the duration of the 218 
trial. We used a decision-model approach ±using evidence from REFORM trial - assuming (i) two health states 219 
(alive and dead); and (ii) the initial podiatry intervention, when displacing usual care, is expected to continue to 220 
bring gains of 0.0129 QALYs per patient per year and incur costs of £251 more per year when alive (e.g. 221 
incremental cost estimates in the trial are considered fixed over the five years).  222 
 223 
RESULTS 224 
 225 
Patient population and missing data 226 
The analysis was based on the 1010 trial participants (493 intervention vs 517 usual care). Twenty four participants 227 
died during the trial [9 (1.8%) intervention vs 15 (2.9%) usual care]. The proportion of participants with complete 228 
data decreased with follow-up: from 72.0% (baseline) to 54.4% (12 months) for the intervention group; and from 229 
71.8% (baseline) to 61.3% (12 months) for the usual care group. The missing data followed non monotonic pattern 230 
(i.e. there were participants with missing six month data but complete data at 12 months); showing that complete 231 
case assessment would be, as a minimum, inefficient as it would discard observed data from individuals with  232 
some missing outcomes. The results of a logistic analysis regression showed that participan ts that were older (OR 233 
1.04; 95% CI 1.02 to 1.06), with lower EQ-5D at baseline (OR 0.68; 95% CI 0.35 to 1.32), and those with a history 234 
of falling (OR 1.26; 95% CI 0.89 to 1.77) were more likely to have missing QALY data. This suggests that data 235 
are unlikely to be MCAR.  236 
 237 
Resource use and costs 238 
In total, 413 out of 493 (83.8%) participants allocated to the intervention had at least one visit to the podiatry 239 
clinic and 183 (37.1%) had at least two. A total of 260 participants received a new pair of shoes. Moreover a total 240 
of 241 participants also received a pair of insoles: X-Line red (n = 23), X-Line blue (n = 209) or Formthotics 241 
insoles (n = 9). They also received resistive therapy bands and therapy balls for the exercises. The intervention 242 
cost on average £115.50 (SD £33.06), and £155.79 (SD £55.02) when the price of the shoes (societal perspective) 243 
was included (Table 2). On average intervention participants had more hospital admissions, outpatient visits and 244 
A&E attendances related to falls than usual care participants over the trial duration, but had on average fewer 245 
falls-related visits to the GP (Table 3). In total, 413/493 (83.8%) participants allocated to the intervention group 246 
had at least one visit to the podiatry clinic, and 183/493 (37.1%) had at least two. Costs associated with falls-247 
related hospital inpatient stay and the intervention itself were the major cost drivers for the analysis.  248 
 249 
Effectiveness 250 
At baseline, participants reported problems in mobility (59.7% intervention vs 56.9% usual care) and pain (78.4% 251 
intervention vs 56.6% usual care) more than in other dimensions. The intervention showed a reduction in the 252 
number of participants reporting problems from baseline to 12 months both for mobility (11% intervention vs 1% 253 
usual care) and pain (15% intervention vs 10% usual care). The likelihood of remaining in perfect health decreased 254 
over time; however the reduction in the number of participants in perfect health in the intervention group (7.4%) 255 
was lower than for the usual care group (17.7%). The data also showed that improvement in anxiety/depression 256 
was proportionally greater than the other dimensions, especially in the intervention group: 19% reduction in 257 
number of participants reporting anxiety problems compared to 1.5% reduction in the usual care group.  258 
Participants in the intervention group started from a lower baseline utility on average (0.67 intervention vs 0.70 259 
usual care); differences in HRQoL were very small across the 12 month follow-up and the 95% CIs overlap at 260 
each time point (Figure 1). At the end of the trial, the difference in QALYs (intervention ± usual care) when 261 
controlling for baseline utility (for available cases: n=377 intervention vs n=415 usual care) showed a marginally  262 
higher QALY gain for the intervention group (0.008 QALY gain; 95% CI -0.009 to 0.026).   263 
 264 
Cost-effectiveness and uncertainty 265 
The incremental analysis (Table 3) shows that on average, the intervention cost £252.17 more per participant 266 
when compared to usual care (95% CI £-69.48 to £589.38); but yields slightly greater benefits, namely 0.012 of 267 
a QALY (95% CI -0.00 to 0.03) when adjusted for all covariates (including baseline utility). Therefore, the ICER 268 
for the base case analysis was estimated at £19,494 per additional QALY. In order to take uncertainty into account, 269 
the paired bootstrapped costs and QALYs were plotted on the cos t-effectiveness plane and the corresponding 270 
probability that the intervention is more cost-effective than usual care in a cost-effectiveness acceptability curve 271 
was presented graphically (Figure 1). The probability of the intervention being cost -effective is 65% at the £30,000 272 
NICE WTP threshold. Several sensitivity analyses were undertaken to test the impact of different assumptions 273 
about costs and imputation (Table 4). None of these analyses markedly changed the ICER or the probability of 274 
cost-effectiveness, except the complete-case which indicated that the Intervention was dominated by usual care.  275 
 276 
Cost per fall averted 277 
The intervention was both more costly and more effective (mean incremental effect 0.19 falls averted per person 278 
year; 95% CI -0.05 to 0.44) than usual care, with an incremental cost per fall averted of £1,253.82 (ICER).  279 
 280 
HRQoL beyond the trial 281 
At year five the difference in HRQoL between the intervention and usual-care groups observed in the trial was 282 
predicted to remain higher for patients allocated to the intervention group (0.0117 QALYs) than the usual care 283 
group. The expected incremental cost-effectiveness of the podiatry intervention was £21,460 per QALY gained.  284 
 285 
DISCUSSION 286 
 287 
REFORM is the largest study to evaluate the cost-effectiveness of a multifaceted podiatric programme to reduce 288 
the risk of falling. Over the 12 month follow up, the podiatric programme cost £252.17 more per participant than 289 
usual care, but led to an average improvement of 0.012 QALYs. These findings suggest that the podiatric 290 
programme costs £19,494 for every additional QALY gained. Therefore, given the NICE WTP threshold, our 291 
base-case results suggest that, on average, the podiatric programme could represent a cost -effective use of NHS 292 
resources. However, the uncertainty around the trial estimates means that the probability of the intervention being 293 
cost-effective is 65% for a threshold of £30,000 per QALY gained.  294 
 295 
REFORM was a pragmatic trial conducted across ten sites that adhered closely to its novel design (a cohort 296 
randomised trial), which aimed to reduce the incidence of attrition, and  provided a robust design to evaluate this 297 
podiatric intervention. The engagement of participants with the intervention was high , with 84% of intervention 298 
participants attending at least one trial podiatry appointment. Intervention participants were asked at 3, 6 and 12 299 
months post-randomisation how many times a week they typically undertook the prescribed foot and ankle 300 
exercises.  At 12 months, compliance with the exercise component was reasonable (29% reported performing the 301 
exercises at least three times a week, and 75% at least once a week).  An instrumental variable CACE analysis 302 
approach was used for the primary trial analysis to account for non-compliance with the intervention (defined as 303 
not attending a trial podiatry appointment).  In this analysis , the intervention was seen to have a marginally greater 304 
effect than in the ITT analysis (incidence rate ratio 0.86, 95% CI 0.69 to 1.06; p=0.16).   305 
 306 
There are a number of potential limitations with our analysis to note. The first  caveat relates to the problem of 307 
missing data. This is a common problem in trial-based economic evaluations that is amplified where there are 308 
frequent assessments, as here. The difficulties in dealing with missing data are driven by the fact that the true 309 
mechanism is usually unknown given the observed data. The pattern of missing data was analysed according to 310 
economic guidelines to ensure that REFORM data support the main assumption that drives the MI mechanis m 311 
assumed for our base case analysis . This analysis shows that data is unlikely to be MCAR, which in turn suggest 312 
that CC analysis might lead to biased estimates. The analysis also showed that missing data followed a non-313 
monotonic pattern, indicating that even if complete case analysis was unbiased, it would be inefficient as it 314 
discards observed data from patients with some missing outcomes. Finally the fact that outcome can be predicted 315 
by baseline variables suggest that MI is the best approach for the analysis, as it can handle non-monotonic missing 316 
data while incorporating the uncertainty around the unobserved data and maintaining the correlation structure. It 317 
is therefore very unlikely that assumptions regarding missing data will change the conclusions of the base case 318 
analysis.  319 
 320 
The second limitation relates to the duration of the study, as one year might be considered too short to  account for 321 
any differences in costs and HRQoL that might be expected with such an intervention. The analysis shows that 322 
the podiatry intervention has a positive impact on HRQoL as measured by the EQ-5D, providing improved levels 323 
of mobility and anxiety and depression in the intervention group. Furthermore the improvement in anxiety and 324 
depression was proportionally greater than the other dimensions. This might be a chance finding but it is possible 325 
that the added reassurance of contact with a health professional, or a decreased likelihood of experiencing at least 326 
one fall, together with the improved levels of mobility, may have led to a decrease in anxiety in the intervention 327 
group. Although cost-effectiveness was demonstrated based on QALYs gained and not necessarily on reducing 328 
IDOOV IDOOV FRXOGSRWHQWLDOO\KDYHDQHJDWLYHHIIHFW RQSDWLHQWV¶+54R/ DQGDQ\LQWHUYHQWLon to improve this is 329 
worthy of consideration. In order to account for the limitation related to the duration of the trial we explored how 330 
the differences in HRQoL observed in REFORM may evolve beyond the trial. The extrapolation of the within  331 
trial HRQoL estimates indicates that the podiatry intervention remains cost-effective at five years. Nonetheless, 332 
the value for money of the intervention decreases with time, as this was only a conservative projection that 333 
excludes potential costs savings associated with the intervention. It is notable, however, that a large proportion of 334 
the intervention costs are incurred during the first year. Furthermore, the mean incremental effect of the 335 
intervention (e.g 0.19 falls averted per person year) observed in the study, which might be interpreted as only 336 
slight clinical significance, was obtained with an incremental cost per fall averted of £1,253.82. In terms of value 337 
for money, this spending on the care of falls may account for approximately 26 visits to a podiatrist b ased on 338 
current NHS reference costs . This also shows that there are other potential cost savings that can emerge from the 339 
trial that make it more likely that the intervention would yield long-term cost savings for the NHS.  340 
 341 
REFORM findings to some extent support those of Spink and colleagues [5], however this study did not include 342 
an economic evaluation. To the best of our knowledge there is no evidence that specifically focusses on the cost-343 
effectiveness of podiatry-related programmes in relation to falls  prevention. Previously reported economic 344 
evaluations have mostly looked at exercise programs founded on the home-EDVHG³2WDJR([HUFLVH 3URJUDPPH´  345 
[28-32] which has been proven to be cost-effective in people aged over 80 years. Similarly there is a form basis 346 
to consider exercise programmes as a cost-effective intervention in reducing fall-related injuries among 347 
community-dwelling older women [33]. These evaluations have reported cost-effectiveness in terms of cost per 348 
fall averted. However there are concerns about the lack of ability of cost-effectiveness analysis to inform decision 349 
makers on whether the strategy for fall prevention represents good value for money compared to other health care 350 
programmes. Cost-utility analysis, based on QALYs ± which capture the value of improvements in morbidity and 351 
mobility - can facilitate the comparison of different health care interventions and therefore are the preferred  352 
method to guide resource allocation within the health care systems. The results of previous cost-utility analyses 353 
have found group-based exercise programmes to be cost-effective for fall prevention for patients at high risk of 354 
falling (e.g. previously fallen) [34] and for older women [35]. It is difficult to assess how these economic analyses 355 
compare with our analysis as there are essential differences in the methods, interventions and comparators, and 356 
populations across studies. However, a Cochrane review looking at falls prevention strategies (none of which  357 
were similar to the multifaceted podiatry intervention investigated in REFORM) concluded that, similar to 358 
REFORM, there was some evidence that these were cost-saving during the trial period and could be cost-effective 359 
over the participantV¶ remaining lifetime [36].  360 
 361 
There is a need to identify cost-effective means for preventing falls to guide appropriate use of limited NHS 362 
resources. From this analysis, we conclude that the podiatry programme could represent a cost-effective option 363 
within the NHS to reduce the risk of falling among older people. In terms of clinical practice, there is also potential 364 
for the cost of the intervention to be further reduced if podiatry assistants rather than the podiatrist undertook the 365 
DVVHVVPHQWRI SDUWLFLSDQW¶V IRRWZHDU DQG PHDVXULQJ RUGHULQJ DQG ILWWLQJ of new footwear. However, the 366 
differences in benefits between the podiatry intervention and usual care are small and although the intervention is 367 
more cost-effective than usual care, decision makers should be aware of the uncertainty associated with our results. 368 
Despite the promising results, future research on long term impact of the intervention on HRQoL and costs would 369 
strength the results of the current economic evaluation.   370 
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